PYPD — PolyPid Ltd.

Summary of PolyPid's Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025:

  • Research and Development (R&D) expenses: $6.2 million (down from $7 million in Q4 2024).
  • General and Administrative (G&A) expenses: $1.8 million (up from $1 million in Q4 2024).
  • Marketing and Business Development expenses: $0.6 million (up from $0.2 million in Q4 2024).
  • Net loss: $8.5 million or $0.41 per share (compared to a net loss of $8.5 million or $1.13 per share in Q4 2024).

• Full Year 2025:

  • R&D expenses: $23.8 million (up from $22.8 million in 2024).
  • G&A expenses: $7.2 million (up from $4.3 million in 2024).
  • Marketing and Business Development expenses: $2 million (up from $0.9 million in 2024).
  • Net loss: $34.2 million or $2.09 per share (compared to a net loss of $29 million or $4.91 per share in 2024).
  • Cash position as of December 31, 2025: $12.9 million, with an additional $3.7 million raised from warrant exercises post-quarter.

2. Strategic Updates and Business Highlights:

• Successfully completed the SHIELD II Phase III trial for D-PLEX100, achieving primary and secondary endpoints related to reducing surgical site infections.
• Received positive FDA feedback regarding a rolling NDA submission for D-PLEX100, expected to begin by the end of Q1 2026.
• Advanced discussions with potential U.S. commercial partners, reflecting strong interest in D-PLEX100's clinical profile.
• Introduced Kynatrix technology, expanding capabilities beyond the PLEX platform to include long-acting GLP-1 Receptor Agonist programs.
• Appointed Brooke Story as Chairman of the Board, enhancing leadership for commercialization efforts.

3. Forward Guidance and Outlook:

• 2026 is anticipated to be a transformative year, with the rolling NDA submission expected to catalyze further growth.
• The company believes existing cash resources will fund operations into the second half of 2026, supporting upcoming milestones.
• Continued engagement with potential partners is expected to accelerate commercialization readiness.

4. Bad News, Challenges, or Points of Concern:

• Despite a decrease in R&D expenses, the overall net loss increased year-over-year, raising concerns about the sustainability of current spending levels.
• The transition from R&D to commercialization poses inherent risks, including the need for successful partnership agreements and market acceptance of D-PLEX100.
• The company faces competitive pressures in the surgical site infection prevention market, which may impact the uptake of D-PLEX100 post-approval.

5. Notable Q&A Insights:

• The FDA has indicated that the initial label for D-PLEX100 will focus on colorectal surgery, with potential for broader abdominal applications in the future.
• Discussions with potential partners are advancing, with emphasis on selecting partners with strong hospital-based capabilities.
• The Kynatrix platform is positioned as an evolution of the PLEX technology, with ongoing R&D work that has been continuous rather than starting anew.
• Market access strategies will be critical, with expectations that uptake will take time post-approval but could lead to steady growth once established on formularies.

Overall, PolyPid is at a critical juncture, transitioning towards commercialization with promising developments in regulatory and partnership discussions, while also facing financial challenges and market risks.